• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vet Microbiol . Subclass switching enhances protective efficacy of a non-neutralizing H7N9 avian influenza antibody

tetano

Editor, Senior Moderator
Vet Microbiol


. 2026 Aug 2:321:111171.
doi: 10.1016/j.vetmic.2026.111171. Online ahead of print.
Subclass switching enhances protective efficacy of a non-neutralizing H7N9 avian influenza antibody

Yunlong Dou[SUP] 1 [/SUP], Jiangyan Zhao[SUP] 1 [/SUP], Xiaozheng He[SUP] 2 [/SUP], Seung-Un Song[SUP] 3 [/SUP], Erdene-Ochir Tseren-Ochir[SUP] 4 [/SUP], Chang-Seon Song[SUP] 3 [/SUP], Xiufan Liu[SUP] 5 [/SUP], Jiao Hu[SUP] 6 [/SUP], Zenglei Hu[SUP] 7 [/SUP]


Affiliations
Abstract

Non-neutralizing antibodies contribute to protection against the H7N9 subtype avian influenza virus through Fc effector functions. Antibody subclass plays a critical role in determining binding affinity to Fc receptors (FcR) and downstream Fc effector functions. In this study, to assess whether antibody subclass switching can enhance antibody protective efficacy, subclass of a non-neutralizing monoclonal antibody (mAb) against the hemagglutinin of H7N9 virus was switched from IgG1 to IgG2a, and their activity and protective efficacy were assessed. Subclass switching caused no significant changes in antigen binding, hemagglutination-inhibition and virus neutralizing activities of the antibody. The hybridoma-derived mAb conferred no protection against H7N9 virus infection. Interestingly, both IgG2a and IgG1 antibodies produced in CHO cells provided full protection against mortality caused by a sublethal H7N9 virus challenge. Upon lethal challenge, IgG2a antibody conferred 70% protection, whereas its IgG1 counterpart only provided 30% protection. However, both antibodies did not decrease virus loads in mouse lungs. Moreover, compared to the IgG1 antibody, affinity of the subclass-switched IgG2a antibody to FcR was significantly increased, as evidenced by enhanced binding of the antibody to recombinant murine FcγRI and to FcRs on murine macrophages. Our findings highlighted a benefit of subclass-engineering to antibody modification and development of therapeutic antibodies.

Keywords: Antibody; Avian influenza virus; Efficacy; Fc receptor; H7N9 subtype; Non-neutralizing; Subclass switching.




 
Back
Top